In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Patheon increases third-quarter revenues by 18%

This article was originally published in Scrip

Executive Summary

The Canadian pharmaceutical development and manufacturing services firm Patheon has reported an 18% increase of revenues to $195 million in its third quarter ended July 31st, and EBITDA before repositioning expenses of $24.7 million, versus $20.6 million in the same quarter last year. It made a net loss of $14.7 million in the quarter. Commercial manufacturing revenues increased by 15% to reach $157.3 million, driven by strong growth in its European business, while pharmaceutical development services revenues increased by 32% to $37.7 million. Patheon has focused on improving its underlying profitability with a restructuring programme and reducing its headcount, while also investing in staff training and development programmes. It is consolidating its York Mills and Whitby operations in Canada, and its Puerto Rico facilities.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC002180

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel